- Home
- AES vs LEGN Comparison
AES vs LEGN Comparison
Compare AES & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AES | LEGN |
|---|---|---|
| Founded | 1981 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.9B | 5.9B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AES | LEGN |
|---|---|---|
| Price | $14.24 | $19.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $15.88 | ★ $63.08 |
| AVG Volume (30 Days) | ★ 14.6M | 1.7M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.26 | N/A |
| Revenue | ★ $12,233,000,000.00 | N/A |
| Revenue This Year | $5.82 | $46.27 |
| Revenue Next Year | $4.39 | $28.77 |
| P/E Ratio | $11.29 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $9.46 | $16.24 |
| 52 Week High | $17.65 | $45.30 |
Technical Indicators
Market Signals| Indicator | AES | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 51.45 |
| Support Level | $14.05 | $17.46 |
| Resistance Level | $14.81 | $23.68 |
| Average True Range (ATR) | 0.22 | 0.95 |
| MACD | -0.22 | 0.22 |
| Stochastic Oscillator | 3.67 | 41.87 |
Price Performance
Historical ComparisonAbout AES The AES Corporation
AES is a global power company that operates in 15 countries. Its generation portfolio totals over 32 gigawatts, including renewable energy (50%), gas (32%), coal (16%), and oil (2%). AES has majority ownership and operates six electric utilities distributing power to more than 2.5 million customers.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.